NCT00316225

Study of Pemetrexed in Mesothelioma and Lung Cancer Patients With Fluid Around the Lungs or Abdomen

A Phase 2 Study of ALIMTA in Solid Tumor Patients With Stable Third-Space Fluid

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 31 (actual)
• Sponsor: Eli Lilly and Company · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study will test the effects of pemetrexed on mesothelioma and non-small cell lung cancer patients with fluid around their lungs or abdomen.

Conditions

• Non-small Cell Lung Cancer
• Mesothelioma
• Lung Neoplasms

Interventions

Type	Name	Description
DRUG	pemetrexed	500 milligrams per meter squared (mg/m\^2) IV every 21 days for 6 cycles

Timeline

• Start date: 2006-12-01
• Primary completion: 2009-03-01
• Completion: 2009-03-01
• First posted: 2006-04-20
• Last updated: 2010-07-09
• Results posted: 2010-07-09

Locations

3 sites across 3 countries: Denmark, Germany, Spain